Psych Central


Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on April 18, 2014, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • rea: my husband suffers anxiety disorder. he doesn’t work because he’s afraid of so many things....
  • John M. Grohol, Psy.D.: You can choose to deny any medical treatment, even if it will save your life. People choose...
  • Julie: I am not married to a man with ADD BUT I have been in a relationship with a man that does have it.A severe and...
  • Christina B.: People who are turned away from treatment wind up homeless, incarcerated or dead from suicide. Is this...
  • John M. Grohol, Psy.D.: I’m arguing we shouldn’t focus on “serious mental illness,” which is...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 9768
Join Us Now!